Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science
Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science
CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.
馬薩諸塞州劍橋，2024年4月9日 /PRNewswire/ — 總部位於馬薩諸塞州劍橋的開發先進mRNA和細胞工程技術的生物技術公司Factor Bioscience Inc.（“Factor”）今天宣佈，其轉化科學團隊將增加三名成員，該團隊將由加入Factor擔任轉化科學總監的凱爾·加蘭博士領導。
"We are excited to welcome three talented scientific professionals."
“我們很高興歡迎三位才華橫溢的科學專業人士。”
"We are excited to welcome three talented scientific professionals to Factor," said Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor. "Dr. Garland, who is joined by Associate Scientists, Raven Hinkel and Elizabeth Belcher, has deep translational research expertise in mRNA and cell engineering. The addition of Kyle and his team will enhance Factor's ability to support our strategic partners and accelerate our efforts to translate our technologies to new products."
Factor聯合創始人、董事長兼首席執行官馬特·安吉爾博士說：“我們很高興歡迎三位才華橫溢的科學專業人士加入Factor。”“加蘭博士與助理科學家雷文·欣克爾和伊麗莎白·貝爾徹一起加入，在mRNA和細胞工程方面擁有深厚的轉化研究專業知識。Kyle及其團隊的加入將增強Factor支持我們的戰略合作伙伴的能力，並加快我們將技術轉化爲新產品的努力。”
"Their collective experience spans many relevant fields of science, including synthetic mRNA, mRNA cell reprogramming, gene editing, cell manufacturing, immunoengineering, and nucleic acid formulation, among others," said Dr. Christopher Rohde, Co-Founder and Chief Technology Officer.
聯合創始人兼首席技術官克里斯托弗·羅德博士說：“他們的集體經驗涵蓋了許多相關的科學領域，包括合成mRNA、mRNA細胞重編程、基因編輯、細胞製造、免疫工程和核酸配方等。”
Dr. Garland added, "I firmly believe that Factor's extensive portfolio of foundational mRNA and cell-engineering technologies has the potential to revolutionize many areas of biotechnology research and development. I look forward to working with Drs. Angel and Rohde to deploy these powerful technologies through the development of new products."
加蘭博士補充說：“我堅信，Factor廣泛的基礎mRNA和細胞工程技術組合有可能徹底改變生物技術研發的許多領域。我期待與安吉爾博士和羅德博士合作，通過開發新產品來部署這些強大的技術。”
Dr. Garland joins Factor from Eterna Therapeutics, where he headed the Department of Research and Development, managing the entire portfolio of preclinical programs and overseeing all operational aspects of the company's strategic collaborations. He holds a Doctor of Philosophy degree in Chemical Engineering from Vanderbilt University and a Bachelor of Science degree in Bioengineering from Lehigh University.
加蘭博士從Eterna Therapeutics加入Factor，領導研發部，管理整個臨床前項目組合，並監督公司戰略合作的所有運營方面。他擁有範德比爾特大學化學工程哲學博士學位和利哈伊大學生物工程理學學士學位。
About Factor Bioscience
關於因子生物科學
Factor Bioscience develops technologies for engineering cells to promote health and improve lives. For more information, visit .
Factor Bioscience開發了工程細胞的技術，以促進健康和改善生活。欲了解更多信息，請訪問。
SOURCE Factor Bioscience
來源因子生物科學
譯文內容由第三人軟體翻譯。